Ritonavir-boosted antiretroviral therapy with paclitaxel: will it lead to boosted toxicity?

AIDS. 2022 Feb 1;36(2):322-323. doi: 10.1097/QAD.0000000000003115.

Authors

Indy G Murdoch¹, Tom G Jacobs¹, Rosa M Nieuwenhuize², Quirine C van Rossum-Schornagel³, Carolina A M Schurink⁴, Nielka P van Erp¹, David M Burger¹

Affiliations

¹ Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen.
² Department of Medical Oncology, Erasmus MC, University Medical Centre Rotterdam.
³ Department of Internal Medicine, Franciscus Gasthuis & Vlietland.
⁴ Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.

PMID: 34934024
DOI: 10.1097/QAD.0000000000003115

No abstract available

MeSH terms

Anti-HIV Agents* / adverse effects
Antiretroviral Therapy, Highly Active / adverse effects
Drug Therapy, Combination
HIV Infections* / drug therapy
HIV Protease Inhibitors* / adverse effects
Humans
Paclitaxel / adverse effects
Ritonavir / adverse effects

Substances

Anti-HIV Agents
HIV Protease Inhibitors
Ritonavir
Paclitaxel